Sanofi said that its Rilzabrutinib treatment was granted orphan drug designation, which is used in the U.S. by the Food and Drug Administration. The designation is a status assigned to a medicine ...

Sanofi's Qfitlia gains FDA approval, offering fewer injections in hemophilia care. Check out my recommendation for SNY stock.

The undisclosed target is a central regulator of inflammation that is distinct from the previously disclosed STAT6 programNurix DEL-AI drug ...

Nurix Therapeutics (NRIX) announced that Sanofi (SNY) has exclusively licensed an undisclosed Nurix program targeting a previously undruggable ...

The move comes amid HHS Secretary Robert F. Kennedy Jr.’s decision to force out the top official responsible for reviewing such vaccines, Dr. Peter Marks, and put his deputy Julie Tierney on ...

The U.S. Food and Drug Administration has approved Qfitlia (fitusiran) for routine prophylaxis to prevent or reduce the ...

Wockhardt will deepen its novel antibiotics pipeline over the next five years and focus on building a biosimilar business for ...

EconoTimes is a global, independent publication that delivers comprehensive news, analysis, and insights on the economy, finance, and markets. Based in Korea, we offer a unique perspective on global ...

Discover March 2025’s top biotech deals, featuring major collaborations in small molecules, bispecific antibodies and protein ...

Dow Jones Newswires is a market-moving financial and business news source, used by wealth managers, institutional investors and fintech platforms around the world to identify trading and investing ...

Rilzabrutinib granted orphan drug designation in the US for two rare diseases with no approved medicines <li /> Designation granted for w ...

After some high-profile crashes, the one-time biotech darling is inching toward success with its Hunter syndrome treatment, ...